Table 1

Summary of female liver donor demographics and EM-652 glucuronidation activity.

Donor	Age	Smoker	Alcohol Consumption	Medicine	Glucuronide formation		Ratio EM-652-7-G/ EM-652-4′-G
Donor	Age	Smoker	Alcohol Consumption	Medicine	EM-652-4′-G	EM-652-7-G	Ratio EM-652-7-G/ EM-652-4′-G
					pmol/min/mg of protein
Pool (n = 5)	N.D.	N.D.	N.D.	N.D.	15.6 ± 0.3	53.0 ± 2.2	3.4
Patient 1	59	No	Yes	Nifedipine	15.8 ± 0.3	48.4 ± 1.5	3
				Diabetes
Patient 2	65	Yes	No	Glibenclamide, warfarin	36.0 ± 2.3	134.9 ± 5.4	3.7
				Diabetes
Patient 3	52	Yes	No	Insulin, Paroxetine, Buspirone	11.5 ± 1.5	41.6 ± 4.9	3.6
				Diabetes
Patient 4	44	Yes	No	Insulin, sumatriptan succinate, isometheptine mucate/ dichlovalphenazome/acetaminophen, Sulax	9.9 ± 0.1	42.6 ± 1.2	4.3
Patient 5	42	No	No	Clodine	20.9 ± 0.5	86.9 ± 1.1	4.2
Patient 6	49	No	No	Conjugated estrogen, Oxybutynin, Trazodone	19.6 ± 1.0	91.8 ± 5.1	4.7
				Anorexia
Patient 7	34	Yes	No	Lanotil, Diazepam	36.9 ± 1.6	154.9 ± 4.9	4.2
Patient 8	53	No	No	Estrogen	25.7 ± 1.5	100.2 ± 6.5	3.9

The level of EM-652 glucurono-conjugation by female liver was determined for each hydroxyl position of the molecule by incubating microsomal proteins of liver samples (40 mg) and EM-652 (500 mM) for 3 h in presence of UDP-glucuronic acid (2 mM). EM-652-4′-glucuronide (EM-652-4′-G) and EM-652-7-glucuronide (EM-652-7-G) formation was detected and quantified using LC/MS-MS analysis. Values represent the mean of two independent esxperiments ± S.D.

N.D., not determined.